Evidence map›Paper›PMID 29365201›Full record

ArticleJournal of the National Cancer Institute2018

International Cognition and Cancer Task Force Recommendations for Neuroimaging Methods in the Study of Cognitive Impairment in Non-CNS Cancer Patients.

Sabine Deprez, Shelli R Kesler, Andrew J Saykin, Daniel H S Silverman, Michiel B de Ruiter, Brenna C McDonald

Open access · bronzeAbstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 9 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 9 syntheses or guidelines pooled it, 102 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Cancer treatment-related cognitive impairment.Neuro-oncology advances · 2026
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 3 countries.

Sabine DeprezUniversity Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium.
Shelli R KeslerDepartment of Neuro-oncology, University of Texas MD Anderson Cancer Center, Houston, TX.
Andrew J SaykinCenter for Neuroimaging, Department of Radiology and Imaging Sciences and Indiana University Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN.
Daniel H S SilvermanAhmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
Michiel B de RuiterDivision of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Brenna C McDonaldCenter for Neuroimaging, Department of Radiology and Imaging Sciences and Indiana University Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN.
Indiana University Health · USIndiana University – Purdue University Indianapolis · USKU Leuven · BEThe Netherlands Cancer Institute · NLThe University of Texas MD Anderson Cancer Center · USUniversity of California, Los Angeles · US

Funding

Tumor Microenvironment and Metastasis ProgramP30CA082709 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI Sara K Quinney · 1999 to 2026
$59.3M
Training and Career Development CoreU54CA132378 · NCI · CITY COLLEGE OF NEW YORK · PI Kevin H Gardner · 2008 to 2026
$28.9M
Training and Career Development and Education CoreU54CA137788 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ADRIANA ESPINOSA, FRANCESCA M GANY · 2008 to 2026
$28.1M
INDIANA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE (UL1): BPCAUL1RR025761 · NCRR · INDIANA UNIVERSITY INDIANAPOLIS · PI SHEKHAR, ANANTHA · 2008 to 2011
$21.0M
OLDER BREAST CANCER PATIENTS: RISK FOR COGNITIVE DECLINER01CA129769 · NCI · GEORGETOWN UNIVERSITY · PI AHLES, TIM ALAN, MANDELBLATT, JEANNE · 2009 to 2020
$7.3M
Indiana University Center for Pediatric PharmacologyU54HD071598 · NICHD · INDIANA UNIVERSITY INDIANAPOLIS · PI BIES, ROBERT R · 2011 to 2015
$3.8M
EXTRAMURAL RESEARCH FACILITIES IMPROVEMENT: NEUROLOGICAL DISORDERS:ALZ, PDC06RR020128 · NCRR · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI FIFE, ROSE S · 2004 to 2004
$3.7M
Very-long Term Neurocognitive Outcomes in Breast Cancer Survivors (ProbC2)R01CA172145 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI KESLER, SHELLI R, PALESH, OXANA G · 2012 to 2024
$3.3M
Multimodal MRI Biomarker of Mild Cognitive Impairment in Breast CancerR01NR014195 · NINR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KESLER, SHELLI R, WEFEL, JEFFREY SCOTT · 2012 to 2017
$2.5M
Neural Mechanisms of Chemotherapy-Induced Cognitive DisorderR01CA101318 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI SAYKIN, ANDREW J · 2003 to 2007
$2.0M
Machine Learning Comparison of Brain Anatomy in Cancer and Alzheimer's DiseaseR03CA191559 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KESLER, SHELLI R · 2015 to 2016
$160k
Automated Nucleic Acid Extractor System:AutoGenFlex Star/AutoGen Quick-Gene 810S10RR027710 · NCRR · INDIANA UNIVERSITY INDIANAPOLIS · PI CORNETTA, KENNETH · 2010 to 2010
$159k
NCI NIH HHS P30 CA082709NCI NIH HHS R01 CA101318NCI NIH HHS R01 CA129769NCI NIH HHS R01 CA172145NCI NIH HHS R03 CA191559NCI NIH HHS U54 CA132378NCI NIH HHS U54 CA137788NCRR NIH HHS C06 RR020128NCRR NIH HHS S10 RR027710NCRR NIH HHS UL1 RR025761NICHD NIH HHS U54 HD071598NINR NIH HHS R01 NR014195
6 · The paper itself

Abstract

Cancer- and treatment-related cognitive changes have been a focus of increasing research since the early 1980s, with meta-analyses demonstrating poorer performance in cancer patients in cognitive domains including executive functions, processing speed, and memory. To facilitate collaborative efforts, in 2011 the International Cognition and Cancer Task Force (ICCTF) published consensus recommendations for core neuropsychological tests for studies of cancer populations. Over the past decade, studies have used neuroimaging techniques, including structural and functional magnetic resonance imaging (fMRI) and positron emission tomography, to examine the underlying brain basis for cancer- and treatment-related cognitive declines. As yet, however, there have been no consensus recommendations to guide researchers new to this field or to promote the ability to combine data sets. We first discuss important methodological issues with regard to neuroimaging study design, scanner considerations, and sequence selection, focusing on concerns relevant to cancer populations. We propose a minimum recommended set of sequences, including a high-resolution T1-weighted volume and a resting state fMRI scan. Additional advanced imaging sequences are discussed for consideration when feasible, including task-based fMRI and diffusion tensor imaging. Important image data processing and analytic considerations are also reviewed. These recommendations are offered to facilitate increased use of neuroimaging in studies of cancer- and treatment-related cognitive dysfunction. They are not intended to discourage investigator-initiated efforts to develop cutting-edge techniques, which will be helpful in advancing the state of the knowledge. Use of common imaging protocols will facilitate multicenter and data-pooling initiatives, which are needed to address critical mechanistic research questions.

Indexed as

Advisory CommitteesCognitive DysfunctionHumansImage Processing, Computer-AssistedNeoplasmsNeuroimagingPractice Guidelines as TopicPrognosis

Identifiers

PMID29365201
PMCPMC6658857
OpenAlexW2791044913

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.